Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists, will host an investor presentation on Oct. 21, 2026, at 9 a.m. EDT. The event will focus on the company’s proprietary treatments for depression and anxiety, according to an announcement disseminated on behalf of Helus Pharma.
The presentation will highlight HLP003, the company’s proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder, and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder. The event will also feature perspectives from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a question-and-answer session with Helus Pharma executives. The live webcast will be accessible through the company’s website, with a replay available following the presentation. To view the full press release, visit https://ibn.fm/akaNj.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
The investor presentation matters because it offers stakeholders a direct update on two late-stage programs targeting major depressive disorder and generalized anxiety disorder—conditions with significant unmet treatment needs. HLP003’s Breakthrough Therapy Designation from the FDA underscores its potential to address serious depression, while HLP004’s Phase 2 progress signals expansion into anxiety. With key opinion leaders participating, the event could influence how investors and clinicians view the company’s pipeline and the broader serotonergic agonist approach to mental health treatment.
